The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, chief medical and scientific officer at Small Pharma.
In a historic US first, Oregon voters have approved a ballot measure that will decriminalize the personal possession of all currently illegal drugs, including cocaine, heroin, and methamphetamine.
We spoke with Nick Milne, co-founder and CSO at Octarine to learn more about what science says on the therapeutic benefits of psychedelic compounds, why a bio-based approach for manufacturing is advantageous and the challenges associated.
The first basic experiments for the combined CBD and psilocybin study are already underway.
We interviewed Ronan Levy, founder and executive chairman of Field Trip Psychedelics, Inc. to find out more about the therapeutic potential of psychedelics and hear about the drugs undergoing clinical investigation.
Fred Barrett is an assistant professor of Psychiatry and Behavioral Sciences at Johns Hopkins University in Baltimore. In this interview, we discuss his work with the active component of magic mushrooms, psilocybin. Fred explains how this compound affects the brain, its potential to combat visceral pain, and its links to so-called mystical experiences.
Professor David Nutt has never been afraid to stick his head above the parapet on the topic of drugs. His repeated calling-out of the failures of contemporary drug policy has seen him butt heads with academics and politicians alike. In this interview with Professor Nutt, we discuss pot, policy and the potential of psilocybin.
How does LSD affects a person's mood? And how can mushrooms could boost creativity? We ask Maastricht University's Professor Johannes Ramaekers, who recently collaborated with the UK-based Beckley foundation to examine the effects of microdosing.
In our latest interview series, we discuss the potential of psychedelics to revolutionize clinical neuroscience with thought leaders in the field. In this first interview of our series exploring the Neuroscience of Psychedelics, we talk to Johns Hopkins Associate Professor Gul Dölen, who has spent years exploring the effects of MDMA on the mammalian (and more recently, cephalopod) brain.